X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

OVID

Closed

Ovid Therapeutics Inc

0.316
-0.014 (-4.24%)
Last Update: 01 Jul 2025 23:23:00
Yesterday: 0.3299
Day's Range: 0.3123 - 0.3336
Send
When Written:
 
2.53
Ovid Therapeutics Inc. is a biopharmaceutical company that focuses on developing treatments for rare neurological disorders. The company was founded in 2014 and is headquartered in New York City. Ovid's lead product candidate is OV101, a drug that is being developed for the treatment of Angelman syndrome and Fragile X syndrome, two rare genetic disorders that affect cognitive and behavioral function. OV101 is currently in Phase 2 clinical trials for both indications. Ovid also has a pipeline of other drug candidates in development for rare neurological disorders, including CDKL5 deficiency disorder and tuberous sclerosis complex. The company is committed to advancing innovative therapies that address unmet medical needs and improve the lives of patients and their families. Ovid is publicly traded on the NASDAQ stock exchange under the ticker symbol OVID.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X